@article{2c2bdd5084e14114871937285996bcb2,
title = "Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?",
abstract = "We sought to determine if the absence of hypertension in older adults can be used to identify those at lower risk of atherosclerotic cardiovascular disease (ASCVD). We identified participants ≥75 years old free of cardiovascular disease (CVD) in the National Institutes of Health Pooled Cohorts with and without hypertension. We assessed the association between systolic blood pressure (BP), diastolic BP, and cardiovascular events using multivariable modeling. The association between predicted ASCVD risk and observed events was compared. Of 2,667 adults aged ≥75 years, 67.9% had hypertension. Lower systolic BP correlated with lower CVD event rates. ASCVD predicted risk score and systolic BP were both independently associated with ASCVD event rates. Among adults with similar ASCVD predicted risk estimates, those without (vs with) hypertension had lower observed event rates across the predicted risk spectrum. The absence of hypertension may help refine the risk stratification of older adults, particularly those with intermediate predicted risk.",
author = "Nanna, {Michael G.} and Navar, {Ann Marie} and Daniel Wojdyla and Nelson, {Adam J.} and Sullivan, {Alex E.} and Peterson, {Eric D.}",
note = "Funding Information: Dr. Nanna was supported during the conduct of this study by the NIH training grant T32-HL069749 . Dr. Navar is funded by NIH K01HL133416-01 . Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MG Nanna: Dr. Nanna is supported by NIH training grant T-32-HL069749. AM Navar: Research Grant: Significant; Amarin, Janssen, Amgen, Sanofi, and Regeneron Pharmaceuticals. Consultant/Advisory Board: Significant; Amarin, Amgen, Esperion, Janssen, The Medicines Company, Novartis, Pfizer, Novonordisk, AstraZeneca, Sanofi, and Regeneron. D Wojdyla: No relationship(s) to disclose. AJ Nelson: No relationship(s) to disclose. AE Sullivan: No relationship(s) to disclose. ED Peterson: Research Grant: Significant; Amgen, Sanofi, Astrazeneca, Merck, and Janssen. Consultant/Advisory Board; Modest; Amgen. AstraZeneca, Merck, Novartis, Pfizer, Janssen and Sanofi. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2021",
month = mar,
day = "1",
doi = "10.1016/j.amjcard.2020.11.027",
language = "English (US)",
volume = "142",
pages = "83--90",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
}